.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Focused ultrasound neuromodulation represents a revolutionary frontier for treating complex neurological disorders. This non-invasive technology uses acoustic energy to target deep brain structures precisely. However, most preclinical research relies on healthy animal models. Consequently, understanding how a diseased brain reacts differently than a healthy one is essential for clinical progress.
Recent research investigated how Parkinson’s disease (PD) impacts the efficacy of focused ultrasound neuromodulation. Scientists used a unilateral dopamine depletion model to compare responses between healthy and diseased mice. They specifically targeted the left external globus pallidus (GPe) using a wearable device. Interestingly, the results showed that the disease state completely changed the brain's response to the intervention.
In mice with Parkinson’s, the stimulation significantly inhibited GPe calcium activity for approximately three minutes. Furthermore, this physiological change led to dramatic motor improvements. The researchers observed a reduction in ipsilateral circling that persisted for at least 50 minutes after the session. In contrast, healthy mice showed no significant changes in calcium levels or rotational behavior.
One major concern with any deep-brain intervention is the potential for tissue damage. Fortunately, histological analysis confirmed that this specific protocol caused no neuronal damage or inflammation. There was no evidence of astrocytic activation or microglial proliferation in either group. These safety findings support the potential for translating this technology into human clinical trials.
Notably, the transient inhibition of the GPe appears to correct the pathological overactivity typical of the Parkinsonian state. This selective response highlights why evaluating neuromodulation strategies in relevant disease models is critical. Therefore, future therapies must account for the specific neurochemical environment of the patient’s brain to ensure maximum therapeutic benefit.
In this study, the inhibition of brain cell activity lasted for three minutes, while the improvements in motor movement lasted for 50 minutes after stimulation.
No. Histological exams revealed no signs of cell death, scarring, or immune system activation in the brain regions targeted by the ultrasound.
The ultrasound appears to correct specific imbalances caused by dopamine loss. Because healthy mice do not have these imbalances, the stimulation does not produce the same inhibitory or behavioral effects.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice and is not intended to replace professional judgment or treatment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
New research shows focused ultrasound neuromodulation selectively inhibits GPe activity and improves motor function in Parkinson's mice, but not in healthy ...
7 months ago
A new study reveals that lipid-related metabolic dysregulation, marked by elevated TG/HDL-C ratio and glymphatic changes, independently impacts survival in idiopathic normal pressure hydrocephalus.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
A meta-analysis of 13 propensity score-matched studies shows ViV-TAVR delivers lower early mortality and reduced bleeding compared to redo-SAVR for degenerated bioprosthetic aortic valves, though long-term hemodynamics warrant careful anatomical and patient-centered evaluation.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
